If you have been reading about GLP-1 receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-28. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Len Butt (1910–1994), footballer, who played over 370 games, including 150 for Macclesfield Town Sir Alex Ferguson (born 1941), former footballer who played 317 league games and manager of Manchester United for 26 years Chris Nicholl (1946–2024), footballer who played 706 games Terry Nicholl (born 1952 in Wilmslow), footballer, played over 450 games Andy Fanshawe (1963–1992), a British mountaineer, attended Wilmslow Grammar School Liz Blatchford (born 1980 in Wilmslow), professional triathlete Danny Whitaker (born 1980 in Wilmslow), footballer, played 671 games, including 400 for Macclesfield Town Park Ji-sung (born 1981), footballer, played 318 games and 134 league games for Manchester United David Horsey (born 1985), golfer who currently plays on the European Tour, lives in Wilmslow Seren Bundy-Davies (born 1994), track and field sprinter at 400 metres, attended Wilmslow High School Sam James (born 1994 in Wilmslow), rugby union player who has played over 250 games; currently with Sale Sharks Millie Turner (born 1996 in Wilmslow), football defender, who has played 180 games for Women's Super League club Manchester United
== See also == Biological half-life, the time it takes for a substance to lose half of its pharmacologic, physiologic, or radiologic activity Effective half-life, the effective radioactive half-life in organisms after accounting for excretion Half-life of knowledge, the amount of time that has to elapse before half of the knowledge or facts in a particular area is superseded or shown to be untrue Half a Life (disambiguation)
εl/w = (D/H)l/(D/H)w−1 = [(δDl + 1)/(δDw + 1)]−1; where εl/w = net or apparent fractionation, δDl = lipid product and δDw = source water. The δDs of common lipid classes found in living organisms are: n-alkyl: −170‰ ± 50‰ (113‰–262‰ more D-depleted than growth water) isoprenoid: −270‰ ± 75‰ (142‰–376‰ more D-depleted than growth water) phytol: −360‰ ± 50‰ (more depleted than the other two categories) Polyisoprenoid lipids are more depleted than acetogenic (n-alkyl) lipids with more negative δDs.
Sources: en.wikipedia.org
=== Other compartmental models === There are many modifications of the SIR model, including those that include births and deaths, where upon recovery there is no immunity (SIS model), where immunity lasts only for a short period of time (SIRS), where there is a latent period of the disease where the person is not infectious (SEIS and SEIR), and where infants can be born with immunity (MSIR). Also, compartments for vaccination, detection, or infected vectors like fleas, ticks, or mosquitoes can be added. Compartmental models can also be used to model multiple risk groups, and even the interaction of multiple pathogens.
The Waitangi Tribunal releases an interim report urging the New Zealand Crown to halt work on the proposed Regulatory Standards Bill and to engage in "meaningful consultation" with Māori. Deputy Prime Minister Winston Peters, Regional Development Minister Shane Jones, Labour Party MP Ingrid Leary attend a reopening ceremony at Hillside Engineering. Pro-Palestine, transgender rights, pay equity and climate change protesters picket the event. 20 May: Foreign Minister Winston Peters joins 22 other foreign ministers and the European Union in calling on Israel to allow a full resumption of aid to the Gaza Strip. Two groups of protesters gather outside the New Zealand Parliament to call for the NZ Government to lower the bowel cancer screening age and oppose the suspension of three Te Pāti Māori MPs. The New Zealand Parliament votes to postpone a debate on the Privileges Committee's decision to suspend three Te Pāti Māori MPs until 5 June, allowing them to participate in an upcoming debate around the 2025 New Zealand budget. 22 May: Finance Minister Nicola Willis releases the 2025 New Zealand budget. The Wellington City Council votes to preserve the historic Begonia House and Khandallah Pool, while making cutbacks in transport infrastructure and renovations to Wellington Zoo. The Council also introduces parking fees for motorcycles in the Wellington CBD. 23 May – The New Zealand Geographic Board and Land Information Minister Chris Penk decline a proposal by the Kororāreka Marae Society to rename Russell to its Māori language name "Kororāreka".
Oxidative phosphorylation works by using energy-releasing chemical reactions to drive energy-requiring reactions. The two sets of reactions are said to be coupled. This means one cannot occur without the other. The chain of redox reactions driving the flow of electrons through the electron transport chain, from electron donors such as NADH to electron acceptors such as oxygen and hydrogen (protons), is an exergonic process – it releases energy, whereas the synthesis of ATP is an endergonic process, which requires an input of energy. Both the electron transport chain and the ATP synthase are embedded in a membrane, and energy is transferred from the electron transport chain to the ATP synthase by movements of protons across this membrane, in a process called chemiosmosis. A current of protons is driven from the negative N-side of the membrane to the positive P-side through the proton-pumping enzymes of the electron transport chain. The movement of protons creates an electrochemical gradient across the membrane, which is called the proton-motive force. It has two components: a difference in proton concentration (a H+ gradient, ΔpH) and a difference in electric potential, with the N-side having a negative charge. ATP synthase releases this stored energy by completing the circuit and allowing protons to flow down the electrochemical gradient, back to the N-side of the membrane. The electrochemical gradient drives the rotation of part of the enzyme's structure and couples this motion to the synthesis of ATP.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.